Industry Wire 230

November 27, 2024 Jake Fishman 0 min read
  1. Obesity drugs could be covered by Medicare under Biden proposal.
  2. How Froot Loops landed at the center of U.S. food politics.
  3. Schwarzenegger joins C-suite at Zimmer Biomet to terminate immobility.
  4. Health systems face tough decisions as layoffs surge in Q4.
  5. Where does Medicare Advantage go from here?
  6. Cone Health names Chief Digital Health & Analytics Officer.
  7. Latest payor mix across all 50 states.
  8. The new nominees at CDC, FDA, and Trump’s pick for surgeon general. 
  9. Digital twins: The key to unlocking end-to-end supply chain growth.
  10. Community Health System CEO to retire after 40 years in healthcare.
Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Population Health March 16, 2026

Where We’ve Been, and Where We’re Going in CV Health March 16, 2026

JACC released its inaugural Cardiovascular Statistics 2026 report covering a wide spectrum of major CV risk factors and conditions, and despite the medical advancements in the last ten years, it’s clear we still have a lot of work left to do. As part of its process, JACC synthesized data from multiple national sources and evaluated […]

Cardiac Imaging March 12, 2026

IVI or Angiography for Complex PCI Guidance? March 12, 2026

New follow-up data from the RENOVATE-COMPLEX-PCI trial suggests that intravascular imaging continues to provide better clinical outcomes for patients with complex coronary lesions five years after their PCI procedure. The RENOVATE-COMPLEX-PCI trial originally randomized 1.6k patients with complex coronary lesions to receive either IVI or angiography guided PCI and found that IVI led to a […]

Heart Failure March 9, 2026

Barostim Boosts QoL and LVEF, but Mortality Benefit Still Unknown March 9, 2026

Strong results from two separate studies on CVRx’s Barostim baroreflex activation therapy suggest the technology might offer symptomatic relief even though its mortality benefit is still up in the air. The first of two Barostim studies discussed at THT 2026, the REBALANCE registry enrolled 435 patients with a low average baseline LVEF, mostly NYHA class […]